A green background with a white border. White text at the top says: 2025 Annual Report Below text says: The board voted to approve the 2025 Annual Report for the Oregon Legislature. The report outlines the board's activities, price trend analyses, and policy recommendations to improve drug affordability across Oregon. To the right is a screenshot of the yellow report cover with a photo of a family.
A green background with a white border. White text at the top says: 2025 Affordability Reviews. Below text says: Board members identified several top priority drugs that present significant affordability challenges for Oregonians: Cosentyx Creon Vraylar Trulicity Lantus SoloStar Their final vote will be at their January 21 meeting. Icons of an injection, pills, and a price tag with three dollar signs.
A green background with a white border. White text at the top says: Next Year. Below text says: The board is already preparing for 2026 affordability reviews, developing a preliminary list of 137 drug products for review based on 2024 data. To ensure patient voices are heard, a major outreach project will launch in spring of 2026 with community meetings in Salem, Redmond, Portland, and Beaverton, and online. An icon of the state of Oregon with hands raised inside. A speech bubble coming from the state with a pill bottle and a price tag with three dollar signs.
A green background with a white border. White text at the top says: Looking Ahead. White text below says: Next PDAB Meeting: January 21, 2026 at 8 am, Register for Zoom Link. Board members will vote on the final list of unaffordable drugs from their 2025 affordability reviews. A white icon of a calendar with the date January 21.
This Wednesday the #Oregon #PDAB met. Here are the highlights:
- Annual Report
- 2025 #Affordability Reviews
- Next Year's Plan
Next meeting: Jan 21, 2026 at 8 am. Zoom link at dfr.oregon.gov/pdab
#Cosentyx #Creon #Vraylar #Trulicity #LantusSoloStar #HealthPolicy
![On August 20,
the Oregon PDAB will review: Trelegy* (Fluticasone furoate; Umeclidinum bromide; Vilanterol trifenatate)
Eliquis* (Apixaban)
Xarelto (Rivaroxaban)
Cosentyx (Secukinumab)
Creon (Pancrelipase [Amylase; Lipase; Protease])
* = No generic currently avaiable](https://cdn.bsky.app/img/feed_thumbnail/plain/did:plc:saxighsaimwdrrzrjed3k5hp/bafkreigapflh5jw25kilqoqrdp2gardzlr3nagpahlneatejaqs45m6sk4)
